Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunologic diseases, today announced the initiation of the ...

BioCryst Pharmaceuticals, a rare disease biotech, shows strong revenue growth from ORLADEYO and a healthy cash position. See ...

Orladeyo, BioCryst's main revenue source, saw impressive growth in 2024, but faces significant competition. Click here to ...

Currently, there are no approved treatments for Netherton syndrome. In 2025, the company plans to advance avoralstat, a plasma kallikrein inhibitor, into a clinical trial of patients with diabetic ...

ORLADEYO net revenue of $124.2 million for Q4 2024 (+36.6 percent y-o-y) and $437.7 million for FY 2024 (+34.3 percent y-o-y)——FY 2025 ORLADEYO ...

Global Hereditary Angioedema Therapeutic Market is valued at approximately USD 4.42 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 8.5% over the forecast period ...

DiaMedica Therapeutics (DMAC) announced the peer-reviewed publication entitled: “Recombinant human tissue kallikrein-1 for treating acute ...

DiaMedica Therapeutics Inc. , a clinical-stage biopharmaceutical company focused on developing novel treatments for severe ischemic diseases, today announced the peer-reviewed publication entitled: ...

AnaSpec-激肽释放酶底物,荧光Z-Phe-Arg-AMC-10 mg相关产品： AS-24137 Glandular Kallikrein Substrate, fluorescent H-D-Val-Leu-Arg-AFC - 10 mg AS-72255 SensoLyte® Rh110 Plasma Kallikrein Activity Assay Kit Fluorimetric ...

Detailed price information for Biocryst Pharma Inc (BCRX-Q) from The Globe and Mail including charting and trades.

Detailed price information for Biocryst Pharma Inc (BCRX-Q) from The Globe and Mail including charting and trades.